{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence","slug":"lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence","published_at":"2026-06-10T07:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/9c65f8f7a7c62f8242e0a6359b50fba61045ca32c38da7df9ad4251c8df73849/eyJlcGlzb2RlSWQiOiI0ZTgyMmZkYi03OThkLTRlNDktODZkOC1jN2MzMWUwOGMxMGUiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyODY1OWExMDBjMTVjNWJhYWJiYWUwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTlfXzIxLTEyLTI1Lm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/9c65f8f7a7c62f8242e0a6359b50fba61045ca32c38da7df9ad4251c8df73849/eyJlcGlzb2RlSWQiOiI0ZTgyMmZkYi03OThkLTRlNDktODZkOC1jN2MzMWUwOGMxMGUiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyODY1OWExMDBjMTVjNWJhYWJiYWUwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTlfXzIxLTEyLTI1Lm1wMyJ9.mp3","summary":"Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen asset retatrutide —not just for weight loss but also for other indications . Obesity rival Novo Nordisk, meanwhile, held a dinner, during which executives may have convinced analysts that the company is turning a corner after a rough couple of years. Also check out ADA updates from Roche and partner Zealand Pharma, Boehringer Ingleheim , Pfizer (touting results from its Metsera buy), AstraZeneca , Kailera Therapeutics and more . Outside of ADA, the biggest news of the past week came on Tuesday with GSK striking the biggest traditional pharma/biotech M&A of the year so far with its $10.6 billion acquisition of oncology focused Nuvalent Bio. And on Monday, J&J notched a smaller deal, buying out Firefly Bio for $1B. These deals add to continued uptick in M&A seen in biopharma this year, with much of that momentum being driven by Eli Lilly and its GLP-1 cash. At an FDA listening meeting last week on the Commissioner’s National Priority Voucher program, the agency heard multiple calls to pause it . Confusion also still persists around all of the new rare disease pathways , including the new plausible mechanism framework .","meta_description":"Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1502,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}